Menu Search
Equities

IQVIA Holdings Inc

0JDM:LSE

IQVIA Holdings Inc

Actions
  • Price (USD)0.00
  • Today's Change0.00 / --
  • Shares traded0.00
  • 1 Year change-100.00%
  • Beta0.9015
Data delayed at least 20 minutes.
More ▼

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

  • Revenue in USD (TTM)11.09bn
  • Net income in USD191.00m
  • Incorporated2016
  • Employees67.00k
  • Location
    IQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703-8426United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.iqvia.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IQV:NYQ since
announced		Transaction
value
Corezetta Co LtdRumoured19 Mar 201919 Mar 2019Rumoured14.89%--
Novasyte LLCDeal completed12 Mar 201912 Mar 2019Deal completed17.92%--
Data delayed at least 15 minutes, as of Feb 19 2020 23:30 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.